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Background. High attack rates among vaccinated young adults reported during the 2006 mumps outbreak in the
United States heightened concerns regarding mumps vaccine failure.
Methods. Serum specimens from university students and staff were tested for mumps immunoglobulin (Ig) G by
enzyme immunoassay (EIA). A subset of participants vaccinated for5 years and15 years were tested by neutral-
izing antibody (NA) assay. Persons seronegative by EIA were offered a third dose of measles-mumps-rubella vaccine
(MMR3), and serum specimens were obtained 7–10 days and 2–3 months after its administration.
Results. Overall, 94% (95% confidence interval [CI], 91%–96%) of the 440 participants were seropositive. No
differences existed in seropositivity rates by sex, age, age at receipt of the second dose of MMR vaccine (MMR2), or
time since receipt of MMR2 (P  .568). The geometric mean titer (GMT) of NA among persons vaccinated with
MMR2 during the previous 1–5 years was 97 (95% CI, 64 –148), whereas, among those vaccinated15 years before
blood collection, the GMT was 58 (95% CI, 44 –76) (P  .065). After MMR3, 82% (14/17) and 91% (10/11) sero-
converted in 7–10 days and 2–3 months, respectively.
Conclusions. Lower levels of NA observed among persons who received MMR2 15 years ago demonstrates
antibody decay over time. MMR3 vaccination of most seronegative persons marked the capacity to mount an anam-
nestic response.
Mumps is an acute viral illness and is classically mani-
fested by fever and inflammation of the salivary glands.
Although usually a mild disease, mumps can cause com-
plications (e.g., orchitis, encephalitis, and meningitis
[1]). In the United States in 1967, the modified live Jeryl
Lynn strain of mumps vaccine was licensed, and in 1977
the Advisory Committee on Immunization Practices
recommended routine vaccination of all children aged
12 months with combined measles-mumps-rubella
(MMR) modified live vaccine [2]. In 1989, a 2-dose
MMR vaccination schedule was recommended for
school-aged children and college-aged students for mea-
sles control [3]. Under this 2-dose MMR schedule, most
children and adolescents now receive 2 doses of mumps
vaccine. Epidemiologic data indicate that the routine use
of mumps vaccine has decreased the incidence of
mumps by 99%, such that by 2003 a historic low was
reached in the United States, with 231 cases reported [4].
Despite the achievement of vaccination coverage lev-
els for at least 1 dose of mumps vaccine of90% among
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children aged 19 –35 months since 1996 [5–7] and high vaccina-
tion coverage among schoolchildren, a large mumps outbreak
(5000 cases through the end of July 2006) recently occurred in
the United States, affecting mainly Midwestern states [8, 9]. The
highest attack rate was reported among persons aged 18 –24
years, the majority of whom were college or university students
who had been vaccinated with 2 doses of MMR. High attack rates
among highly vaccinated young adults during this outbreak
raised concerns regarding the mumps vaccine failure.
Antibody determinations are frequently used as surrogate
measures of immunity to viral infections. Although the immune
correlates of protection against mumps disease have not been
defined, virus neutralizing antibody (NA) appears to be a rea-
sonable marker. Vaccine failure can be classified as primary or
secondary. Primary vaccine failure is the lack of an immunologic
response appropriate to vaccination. The antibody response to
mumps virus infection among such persons can be best charac-
terized as that of an immunologically naive person; an IgM re-
sponse and decreased levels of low-avidity IgG are expected [10].
Secondary vaccine failure is the failure to maintain effective im-
munity over time despite having an initial immune response.
Among these persons, an IgM response after mumps virus infec-
tion might be present to varying degrees or it might be absent,
and an increased level of high-avidity IgG is usually observed.
IgG avidity testing can be used to differentiate between primary
and secondary vaccine failure [10].
Although no more than 10 cases have been reported annually
since 1975, Nebraska was one of multiple states in the Midwest
affected by the outbreak in 2006. One Nebraska university with a
2-dose MMR immunization requirement since 2002 had not
reported mumps cases during 2006. This university setting pro-
vided an excellent opportunity to evaluate the persistence of
mumps antibodies induced by MMR vaccination and to docu-
ment measurable declines in mumps antibody levels that might
be indicative of waning immunity and, consequently, of in-
creased susceptibility to mumps virus infection. Our objectives
were (1) to evaluate the persistence of mumps antibody among
persons aged 19 –30 years by correlating antibody levels with
time since the previous dose of MMR vaccine and (2) to charac-
terize vaccine failure by evaluating, among seronegative persons,
the serologic response after challenge with a third dose of MMR
vaccine (MMR3).
SUBJECTS, MATERIALS, AND METHODS
Study population. A convenience sample of volunteer univer-
sity students and staff was included in the study. Because consent
can be given by persons aged19 years in Nebraska and because
persons aged 30 years were more likely to have antibody in-
duced by wild mumps virus infection instead of vaccination,
persons 19 –30 years old were targeted for enrollment. Enroll-
ment criteria included being a university student or staff aged
19 –30 years and having a documented history of receipt of 2
doses of MMR vaccine.
Study design. All university students and staff were notified
of the study and enrollment criteria by a E-mail message. After
informed consent was obtained, a blood specimen was collected
from each study participant. Blood specimens were centrifuged
at the study site, and the resultant serum specimens were
shipped to the Centers for Disease Control and Prevention
(CDC) for mumps IgG antibody testing by EIA. To examine IgG
antibody levels by time since vaccination, a subset of specimens
from participants vaccinated5 years and15 years before en-
rollment were tested at the Food and Drug Administration for
NA levels by plaque reduction neutralization test (PRNT).
Participants without evidence of mumps antibody by EIA
were offered MMR3, and blood specimens from vaccine recipi-
ents were obtained 7–10 days and 2–3 months after vaccination.
Serum specimens were processed at the study site and forwarded
to the CDC for mumps IgM and IgG antibody measurement by
EIA.
Data collection. At the time of enrollment, participants
completed a questionnaire that included the following: name,
date of birth, date and place of mumps-containing vaccination,
country of birth, date of entry into the United States (if not born
in the United States), history of mumps disease, race/ethnicity,
and sex. The university vaccination records were used to obtain
the vaccination history of each participant.
Laboratory testing. For the detection and qualitative deter-
mination of IgG antibody to mumps virus in serum specimens, a
commercially available indirect assay (Mumps IgG ELISA II As-
say; Wampole Laboratories) was used. This EIA had been re-
ported to favorably compare with PRNTs regarding sensitivity
(70%) and specificity (96%) for detection of mumps antibody
[11]. The cutoff points for mumps IgG antibodies based on in-
dex standard ratio (ISR) values were as follows: seronegative, ISR
of0.90; indeterminate, ISR of 0.91–1.09; and seropositive, ISR
of1.10.
For quality assurance, all samples with seronegative or inde-
terminate results for mumps IgG were retested with an equal
number of randomly selected positive serum specimens. If re-
tested specimens had positive results, they were reported as IgG
seropositive. Serum specimens testing either negative or indeter-
minate were considered negative for our investigational pur-
poses.
Serum specimens from recipients of MMR3 were tested for
mumps IgM and IgG as a measure of primary and secondary
antibody responses. A CDC in-house mumps IgM capture EIA,
which uses recombinant mumps nucleocapsid protein as anti-
gen, was used to detect mumps IgM. The format for the mumps
assay was based on an IgM capture assay for measles that has
been described elsewhere [12], except that the assay used a cell
lysate containing baculovirus-expressed mumps nucleoprotein
as the viral antigen and that the detector antibody was a mono-
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clonal antibody directed against the mumps nucleoprotein (N5;
gift of J. Wolinsky, University of Texas Medical School, Hous-
ton). Serum specimens were considered to be negative for
mumps IgM if the ratio of optical density (OD) values for posi-
tive (P) mumps-antigen wells divided by negative (N) mumps-
antigen wells (P/N) was 3.0 and the OD value P  N was
0.10. Specimens were considered to be positive for mumps
IgM if the ratio of P/N was 3.0 and the P  N value was
0.093. Serum specimens fulfilling only 1 of the 2 positivity
criteria were considered to be indeterminate. As an additional
control for antibody response after MMR vaccination, measles
IgG antibody levels were measured using a Wampole Measles
IgG ELISA (Wampole Laboratories). For certain analyses, the
mumps IgG antibody level was stratified using the ISR values
into 3 groups, as follows: low, ISR of 1.10 –2.5; intermediate, ISR
of 2.6 – 4.4; and high, ISR of4.5.
PRNT was used to measure neutralizing anti-mumps anti-
body levels. Briefly, serum was thawed at room temperature and
heated at 56°C for 45 min to inactivate the complement. Two-
fold serial dilutions of serum (or medium alone as a negative
control) were mixed with equal volumes of 30 pfu of the at-
tenuated Jeryl Lynn mumps virus strain (the mumps component
of MMR vaccine), to achieve a final dilution range of 1:4 –1:512.
The serum/virus mixtures were incubated at 37°C in 5% CO2 for
1 h and then placed on Vero cell monolayers in 24-well plates
and incubated for 1 h at 37°C in 5% CO2. The serum/virus mix-
tures were removed by aspiration, and cell monolayers were
rinsed with minimal essential medium (MEM) immediately be-
fore being covered with 0.75% Nobel agar in 2MEM (Quality
Biologicals) supplemented with 10% fetal bovine serum. Plates
were then incubated at 37°C in 5% CO2 for 5 days. A second layer
of agar containing 0.01% neutral red (Quality Biologicals) was
added and incubated overnight to visualize the plaques pro-
duced by the remaining infectious virus. For each serum speci-
men, the NA level was determined as the highest dilution of
serum capable of reducing the number of virus plaques by
50%, compared with control values (from virus incubated
with negative control serum). The cutoff point for seropositivity
was a NA level of1:4. Levels of NA to the Jeryl Lynn strain of
mumps virus were classified into 4 groups, as follows: negative,
1:4; borderline positive, 1:4 –1:8; moderate positive, 1:16 –1:
128; and highly positive,1:128. Hereafter, titers are reported as
reciprocal values.
Sample size and statistical analysis. Sample size was cal-
culated to evaluate, at a 5% significance level and 80% power, a
10% difference in the proportion of persons seronegative for IgG
among the 2 groups—vaccinated persons who received the sec-
ond dose of MMR vaccine (MMR2) 5 years and 15 years
before blood collection. Risk factors evaluated for seronegative
EIA results included sex, race/ethnicity, age, age at first dose of
MMR vaccine (MMR1) and at MMR2, time between MMR1 and
MMR2, and time since receipt of MMR2. In addition, the likeli-
Table 1. Seropositive EIA results for mumps IgG among univer-
sity study participants, by characteristic—Nebraska, 2006.
Variable Tested, no.
IgG seropositive
No. % (95% CI) P
Sex .193
Male 169 155 92 (88–96)
Female 271 257 95 (92–98)
Race/ethnicity .366
White 425 397 93 (91–96)
Other 15 15 100 (100–100)
Age .276
19–20 years 171 160 94 (90–97)
21–22 years 175 167 95 (92–98)
23 years 94 85 90 (84–96)
Age at MMR1 .243
1 year 235 225 96 (93–98)
2 year 165 151 92 (87–96)
3 years 40 36 90 (81–99)
Age at MMR2a .797
1–6 years 59 56 95 (89–100)
7–14 years 338 315 93 (91–96)
15 years 42 40 95 (89–100)
Years between MMR1
and MMR2a .515
1–5 years 71 67 94 (89–100)
6 years 368 344 93 (91–96)
Years since receipt
of MMR2a .265
1–10 years 293 277 95 (92–97)
11 years 146 134 92 (87–96)
NOTE. CI, confidence interval; MMR1, first dose of MMR vaccine;
MMR2, second dose of MMR vaccine.
a Data for age at time of administration of MMR2 was unavailable for 1
student.
Table 2. Seropositive EIA results for mumps IgG among
university study participants, by age and time since receipt





% ORa (95%CI) P
Age
19–20 years 94 Referent
21–22 years 95 1.45 (0.57–3.71) .238
23 years 90 0.74 (0.25–2.15) .325
Years since receipt
of MMR2
1–10 years 95 Referent
11 years 90 0.80 (0.32–2.01) .629
NOTE. CI, confidence interval; OR, odds ratio.
a Adjusted for age and years since receipt of MMR2.
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hood of seronegativity was assessed by controlling for age and
years since receipt of MMR2. Arithmetic means were used to
describe ISR values by time since vaccination. To describe NA
levels, GMTs were calculated using log-transformed reciprocal
levels and are reported as back-transformed values. For bivariate
analysis, the tests used were the 2 test for categorical variables,
the Cochran-Armitage test for trend for ordinal variables, and
the t test and Wilcoxon rank-sum test for continuous variables.
Association between ISR and NA levels was examined via Pear-
son correlation. P  .05 was considered to indicate statistical
significance. Data were analyzed using SAS (version 9.1) [13].
RESULTS
A total of 446 persons were enrolled in the study. Of these, 6
(1.3%) were excluded as a result of a history of mumps virus
infection (2 students) or vaccination outside the United States (4
students). Of the 440 persons included in the analysis, 62% were
female, 97% were white, and 98% were born in the United States.
The median age of the participants was 21 years (range, 19 –30
years). The median age at MMR1 vaccination was 1 year (range,
1–27 years) and at MMR2 vaccination was 12 years (range, 1–28
years).
EIA testing. The presence of serum mumps IgG antibody
was determined for all 440 participants. The overall mumps IgG
seropositivity rate was 94% (95% confidence interval [CI], 91%–
96%). In contrast, all 440 participants (100%) were seropositive
for measles IgG. No differences existed in mumps seropositivity
rates by sex or race/ethnicity (table 1). Mumps seropositivity
rates did not differ by age group, age at receipt of MMR1 or
MMR2, time interval between MMR1 and MMR2, or time since
receipt of MMR2. The likelihood of seropositivity was not asso-
ciated with increased time since receipt of MMR2, even after
adjustment for age (table 2).
Although higher mean ISR values were identified among par-
ticipants vaccinated with MMR2 5 years ago, the association
between mean ISR values and time since receipt of MMR2 was
borderline significant (P  .051) (figure 1).
NA levels. Levels of NA to the Jeryl Lynn strain of mumps
virus were measured for 91 persons, who had received MMR2
1–5 years (n  23) or15 years (n  68) before blood collec-
tion. The overall GMT of NA was 66 (95% CI, 52– 85); the titers
did not differ by sex, age at receipt of MMR1 or MMR2, or time
interval between MMR1 and MMR2 (table 3). The titer to the
Jeryl Lynn strain of mumps virus was higher among participants
who had received MMR2 within the previous 1–5 years (GMT,
97 [95% CI, 64 –148]), compared with that among participants
who received MMR215 years earlier (GMT, 58 [95% CI, 44 –
76]); however, this difference was only borderline significant
(P  .065) (figure 2).
Correlation between EIA and NA. Eighty-six (95%) of the
91 specimens tested by both EIA and PRNT were seropositive for
mumps IgG by EIA. Of these, 83 (97%) had NA titers higher than
the borderline positive cutoff (i.e.,8), and 3 (3%) had border-
line positive NA results. Among the 3 specimens with borderline
positive results, 2 had low and 1 had intermediate ISR values.
Among the 86 specimens seropositive by EIA, the median ISR
value was 3, and the GMT of NA was 70. Correlation between
NA levels and ISR values was significant, but the association was
imperfect (ratio, 0.45; P  .01). Among the 5 participants with
Figure 1. Prevalence of mumps seropositive EIA results and index
standard ratio (ISR) values for mumps antibody among 440 university
study participants, by years since receipt of a second dose of measles-
mumps-rubella vaccine—Nebraska, 2006.
Table 3. Geometric mean titers (GMTs) of mumps neutral-
izing antibody among university study participants who re-
ceived a second dose of measles-mumps-rubella vaccine
(MMR2) 5 and 15 years before blood collection
(n  91)—Nebraska, 2006.
Variable Tested, no. GMT (95%CI) P
Sex .561
Male 49 62 (43–89)
Female 42 72 (51–100)
Age at MMR1 .314
1 year 48 67 (47–95)
2 years 30 53 (35–80)
3 years 13 109 (59–203)
Age at MMR2 .610
1–6 years 48 58 (42–80)
7–14 years 18 69 (36–113)
15 years 25 84 (53–135)
Years between
MMR1 and MMR2 .244
1–5 years 53 62 (46–85)
6 years 38 73 (49–109)
NOTE. CI, confidence interval; MMR1, first dose of MMR vaccine.
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seronegative EIA results, none had high NA levels; the median
ISR value was 1, and by PRNT the GMT of NA was 24.
Antibody response after MMR3. Nineteen of the 28 per-
sons who had seronegative EIA results (i.e., negative or indeter-
minate) for mumps IgG received MMR3 1–5 months after the
initial blood collection (mean, 3.5 months). Seventeen persons
(89%) provided a blood specimen 7–10 days after receipt of
MMR3. Of these 17 persons, 3 had seronegative results for IgG
and IgM. Seropositive results for IgG were detected in 14 (82%)
of the 17 persons, and seropositive results for IgM were identi-
fied in 2 (14%) of the 14 persons (figure 3).
At 2–3 months after receipt of MMR3, 13 participants also
provided a third blood specimen. All 9 persons who had been
IgG positive at 7–10 days remained positive at 2–3 months after
MMR3, and 1 of the 2 seronegative persons at 7–10 days had
measurable IgG levels. One of the 2 participants who had been
IgG seronegative at 7–10 days remained negative at 2–3 months.
For these 11 participants, the overall seropositivity rate at 2–3
months was 91% (10/11); all were IgM seronegative. Two par-
ticipants who had provided only a blood specimen 2–3 months
after MMR3 were IgM seronegative and IgG seropositive. The
mean ISR values for participants with paired specimens were 1.3
(95% CI, 1.2–1.5) at 7–10 days and 2.1 (95% CI, 1.6 –2.7) at 2–3
months after receipt of MMR3.
DISCUSSION
The majority (94%) of study participants had seropositive EIA
results for mumps IgG, and the seropositivity rate did not differ
by age, sex, race/ethnicity, age at vaccination, or time since vac-
cination. The majority of seronegative persons vaccinated with
MMR3 were seropositive 2–3 months after its receipt. The IgG
serologic response, without detectable IgM at 7–10 days after
MMR3 and the increased IgG levels 2–3 months after vaccina-
tion, indicates a B cell memory response in most instances. Thus,
no major evidence for primary vaccine failure was observed
among the seronegative persons.
Information regarding long-term persistence of mumps anti-
bodies after a second dose of MMR vaccination is limited. Evi-
dence for secondary vaccine failure can be demonstrated
through epidemiologic investigation of outbreaks by assessing
the vaccination status of case patients and by serologic studies
demonstrating a decline in IgG antibody levels over time. Previ-
ous studies have yielded conflicting findings regarding the asso-
ciation between vaccine failure and time since vaccination, with
some reporting no association during certain outbreaks [14 –17]
and others reported a positive correlation between risk for
mumps virus infection and increasing interval since vaccination
[18 –20]. Existing data indicate that 1 dose of MMR vaccine can
provide persistent antibodies to mumps virus5 years after vac-
cination [21]. A study in Finland identified a rapid decline in
mumps antibody levels within the first year after 1 dose of
mumps vaccine and a lesser decline after a second dose, with an
overall seropositivity rate of 86% at 9 years after a second dose of
mumps vaccine [22].
We did not identify any factor associated with seronegative
results. Although a higher proportion of females with mumps
were reported during outbreaks in the 1980s [14 –16] and in
2006 [8, 9], we did not identify statistically significant differences
in seropositive results or antibody levels by sex that might ex-
plain the preponderance of female patients during the 2006 out-
break.
Postlicensure studies conducted in the United States during
the 1970s and 1980s documented that 1 dose of mumps virus–
containing vaccine was 80% effective in preventing mumps
with parotitis [23]. Although fewer data are available on the ef-
fectiveness of 2 doses of mumps vaccine, estimates of effective-
Figure 2. Geometric mean titers (GMTs) of mumps neutralizing anti-
body and index standard ratio (ISR) values for mumps antibody among 91
university study participants, by years since receipt of a second dose of
measles-mumps-rubella vaccine—Nebraska, 2006.
Figure 3. Description of mumps seropositive results among 17 sero-
negative persons after receipt of a third dose of MMR (MMR3) vaccine—
Nebraska, 2006. Indet, indeterminate.
1666 ● JID 2008:197 (15 June) ● Date et al.
ness range from 88% to 95% [24 –28]. The Jeryl Lynn mumps
modified live vaccine virus and prior mumps virus infection
does not seem to be as effective as the modified live measles
vaccine virus in inducing immunity. Mumps virus infection has
been documented among persons with previous mumps virus
infection [29] and among 2-dose recipients of mumps vaccine.
The 2006 US outbreak demonstrated that mumps transmission
and outbreaks can occur among populations with high vaccina-
tion coverage with 2 MMR doses [8, 9].
Although infection with measles virus has been documented
among recipients of 2 doses [30], high population vaccination
coverage levels have been successful in preventing sustained
measles transmission due to the high effectiveness of the measles
vaccine [31]. The majority of the US population is vaccinated
with MMR vaccine, and measles is considered more infectious
than mumps [32, 33]. Therefore, the difference in mumps dis-
ease patterns cannot be explained by differences in vaccination
coverage levels or infectivity. The difference in seropositive re-
sults between measles and mumps identified in our study (i.e.,
100% for measles vs. 94% for mumps) confirms the differences
in antibody response patterns. However, we cannot assume that
the presence of antibody levels necessarily correlates with pro-
tection. Unlike measles, for which NA level seems to be a useful
correlate of protection [34], a similar antibody-measurement
correlate for mumps immunity is unclear. A prospective study
determined that levels8 by PRNT were protective against clin-
ical mumps [35]. In our study, NA levels were not assessed
among all participants; however, among the 91 participants with
serum tested by both EIA and PRNT, 97% who were seropositive
by EIA had levels8, indicating the likelihood of IgG antibody
levels8 among this university population. In addition, the 6%
EIA-based seronegativity rate identified during this study is sim-
ilar to the failure rate reported among college students who had
received 2 doses of MMR and who had been exposed to a room-
mate with mumps during the 2006 outbreak (CDC, unpublished
data).
All but one person mounted an IgG response after adminis-
tration of MMR3 to seronegative persons. This anamnestic re-
sponse was typified by the rapid appearance of mumps virus–
specific IgG and a general absence of a detectable IgM response
[10, 36 –38] among the majority of participants. This antibody
response was similar to that observed during the mumps out-
break in 2006, thus making laboratory confirmation of clinically
diagnosed mumps challenging because of the lack of IgM and the
presence of IgG at the time when patients sought health care [9].
A rapid IgG response was observed at 7–10 days after MMR3, but
peak antibody activity was not present until sometime between
the 7–10-day and the 2–3-month intervals. Whether these levels
of mumps antibody were maintained after 2–3 months or rep-
resent antibody levels that provide protection against mumps
virus infection is unknown.
Our study has potential limitations. The students and staff
participating in the study represent a convenience sample; there-
fore, results might not be generalizable to other populations. The
possibility of IgG boosting caused by natural mumps virus in-
fection among the study subjects is unknown. Although the uni-
versity was not affected by the mumps outbreak, at the time of
the study, 3 possible (clinically compatible but laboratory nega-
tive) mumps-like cases were reported at the university, and some
cases were reported in the surrounding community. We could
not assess the effect of exposure to such cases on the rate of
seropositive results. The NA test in this study used the Jeryl Lynn
vaccine virus strain; however, preliminary data from another
study determined that higher antibody levels might be needed
for neutralization of the 2006 mumps outbreak strain relative to
the Jeryl Lynn strain [39]. We did not conduct IgG avidity testing
to differentiate between primary and secondary vaccine failure.
The determinants of vaccine-induced mumps immune pro-
tection have not been fully determined. Two doses of mumps
vaccine seem to induce a higher antibody response than 1 dose.
In a mixture model applied to a serological survey in England
and Wales, cohorts eligible for 2 doses of mumps vaccine pre-
sented higher antibody titers than did those eligible for 1 dose
[40]. However, the optimal protective antibody level that might
be required to protect against mumps disease is unknown. Un-
derstanding the protective mumps antibody level is critical to
assessing waning immunity and to estimating the proportion of
susceptible persons among the population. More studies are
needed to confirm the decline of mumps antibody levels over
time after MMR2 vaccination. The failure of the available
mumps vaccine in preventing disease transmission among pop-
ulations with high 2-dose vaccination coverage levels raises a
question regarding the necessity of an additional mumps vaccine
booster or the development of a more effective vaccine. Our
results demonstrated seroconversion among seronegative per-
sons after receipt of a third dose; however, more research is
needed to understand the importance of a third dose and its
relevance for future planning of specific strategies for mumps
prevention.
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